Fatty acid‐binding protein 5 function in hepatocellular carcinoma through induction of epithelial–mesenchymal transition. (4th April 2017)

• Record Type: Journal Article
• Authors: Ohata, Takanori; Yokoo, Hideki; Kamiyama, Toshiya; Fukai, Moto; Aiyama, Takeshi; Hatanaka, Yutaka; Hatanaka, Kanako; Wakayama, Kenji; Orimo, Tatsuya; Kakisaka, Tatsuhiko; Kobayashi, Nozomi; Matsuno, Yoshihiro; Taketomi, Akinobu
• Is Part Of: Cancer medicine. Volume 6:Number 5(2017:May)
• Page Start: 1049
• Page End: 1061
• Publication Date: 2017-04-04
• Subjects: Epithelial‐mesenchymal transition -- fatty acid‐binding protein -- hepatocellular carcinoma -- metastasis -- prognosis; 616.994005
• DOI: 10.1002/cam4.1020
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract : Fatty acid‐binding protein 5 was closely related to the gain of malignant potential through the activation of epithelial‐to‐mesenchymal transition, and also behaved as a significant prognostic and recurrence factor in hepatocellular carcinoma (HCC) patients. FABP5 may serve as a new biomarker of HCC and a potential molecular target for the development of HCC therapies. Abstract: Hepatocellular carcinoma (HCC) is a highly prevalent cancer with poor prognosis. The correlation between overexpression of fatty acid‐binding protein 5 (FABP5) and malignant potential of tumor growth and metastasis in several cancers has been previously reported. However, the correlation between FABP5 expression and HCC malignant behavior remains unknown. We compared FABP5 expression and patient characteristics in paired HCC and adjacent noncancerous liver tissues from 243 patients who underwent surgical resection of primary HCC. Cell proliferation, invasion, and migration assays were performed in HCC cell lines overexpressing FABP5 or downregulated for FABP5. Tumor growths were monitored in xenograft model, and liver and lung metastasis models were established. In the 243 HCC patients, FABP5‐positive staining ( n = 139/243, 57.2%) was associated with poor prognosis and recurrence ( P < 0.0001) and showed positive correlation with distant metastasis, tumor size and vascular invasion ( P < 0.05). Cell proliferation, invasion, and migration in vitro were enhanced by upregulation of FABP5 and decreased by downregulation of FABP5 in HCC cell lines. Similar results in tumor formation and metastasis were obtained through in vivo analyses. PCR array results revealed upregulation of SNAI1 in FABP5‐overexpressing HepG2 cells. Western blot analysis showed significantly increased expression of E‐cadherin and ZO‐1 and decreased SNAI1 expression and nuclear translocation of β ‐catenin by knockdown of FABP5. We revealed a significant role for FABP5 in HCC progression and metastasis through the induction of epithelial‐to‐mesenchymal transition. FABP5 may be a potential novel prognostic biomarker and new therapeutic target for HCC.